Long-Acting/Extended Release Antiretroviral Resource Program
Member Directory - Pharmaceutical Advisory Board
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. |
Dr. Elliot Ehrich is Executive Vice President, Research and Development, Chief Medical Officer at Alkermes. He received his undergraduate degree from Princeton University and a doctorate degree from Columbia University. |
Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989. |
Magali Hickey is the Director of Formulation Development at Alkermes Inc., a global biotechnology organization with a research and development facility located in Waltham, MA. Magali has over 10 years of experience in the pharmaceutical industry with interests focused on development of small molecules into viable drug products. |
Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. Dr. Rooney has been instrumental in the clinical development of the company's antiviral therapies, including treatments for HIV, hepatitis B and influenza. |
Dr. Kimberly Y. Smith MD, MPH is the Vice President for Global Medical Strategy and Head of Research and Development for ViiV Healthcare. In this role she oversees the clinical development of the ViiV marketed and pipeline assets and works closely with the development teams in both GSK and Pfizer. |
Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. |
Peter leads teams investigating novel interventions against HIV-1, within the R&D group of Janssen’s Global Public Health organization. He is project leader for rilpivirine long acting, the injectable nanosuspension formulation being investigated for treatment and prophylaxis against HIV. |